Video Insights
Video Insights
Sandeep Gurram, MDnccRCC | August 13, 2025
Drs. Gurram and Yerram conclude with a discussion on the importance of multidisciplinary care for hereditary kidney cancer.
View More
Sandeep Gurram, MDnccRCC | August 13, 2025
Drs. Gurram and Yerram review options for hereditary kidney cancers, highlight data on bevacizumab plus erlotinib, anlotinib.
Gopa Iyer, MDAdvanced Urothelial Carcinoma | August 7, 2025
Dr. Gopa Iyer discusses his investigation of the relationship between DDR, mUC molecular subtypes and survival outcomes.
Shahid S. Ahmed, MDmCSPC | August 5, 2025
Drs. Ahmed, Ciuro conclude with a discussion on bridging access gaps between academic and community practices.
Shahid S. Ahmed, MDmCSPC | August 5, 2025
Drs. Ahmed, Ciuro discuss criteria for treatment de-escalation, and the emerging significance of PSA nadir as a biomarker.
Sandeep Gurram, MDnccRCC | August 4, 2025
Drs. Gurram, Yerram examine the clinical features and aggressive behavior of FH-deficient renal cell carcinoma and more.
Sandeep Gurram, MDnccRCC | August 4, 2025
Drs. Gurram, Yerram provide an overview of hereditary vs sporadic kidney cancer and highlight key syndromes like VHL, HLRCC.
Sanjay Juneja, MDProstate Cancer | July 31, 2025
At the Oncology Forum, Dr. Sanjay Juneja led a dynamic discussion covering pivotal developments across genitourinary cancers.
Michael Ahdoot, MDNon-Muscle Invasive Urothelial Carcinoma | July 23, 2025
Drs. Ahdoot, Yerram discusses trial data, early adoption, and why en bloc TURBT is a safe option worth trying in practice.
Michael Ahdoot, MDNon-Muscle Invasive Urothelial Carcinoma | July 23, 2025
Drs. Ahdoot, Yerram review trial data and share practical tips for adopting en bloc TURBT across real-world settings.
Loïc Djaileb, MD, PhDProstate Cancer Diagnostics | July 21, 2025
Dr. Loïc Djaileb explores the use of RECIP 1.0 criteria with SPECT/CT and the efficacy of this strategy in monitoring mCRPC.
Valentina Marulanda Corzo, MDRLT | July 18, 2025
Drs. Tagawa and Marulanda Corzo discuss the use of single time-point SPECT/CT dosimetry for 177Lu-PSMA targeted RLT.
Nadine Mallak, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Nadine Mallak talks about 18F-fluciclovine to detect disease in BCR of prostate cancer when the standard of care fails.
Michael Ahdoot, MDNon-Muscle Invasive Urothelial Carcinoma | July 15, 2025
Drs. Ahdoot and Yerram weigh how to approach tumors located in challenging areas, and the role of detrusor muscle sampling.
Michael Ahdoot, MDNon-Muscle Invasive Urothelial Carcinoma | July 15, 2025
Drs. Ahdoot and Yerram discuss the fundamental reasons for adopting en bloc resection in bladder cancer surgery.
Brittany Miles, MDProstate Cancer Diagnostics | July 15, 2025
Dr. Miles highlights the dilemma of managing PC with BCR after prostatectomy but no visible disease on standard imaging.
Shahid S. Ahmed, MDmCSPC | July 10, 2025
Drs. Ahmed and Ciuro discuss the real-world quality-of-life improvements patients may experience after de-escalating therapy.
Shahid S. Ahmed, MDmCSPC | July 10, 2025
Drs. Ahmed and Ciuro explore the rationale and complexity behind treatment de-escalation in de novo oligometastatic HSPC.
Axel Bex, MD, PhDLocalized Renal Cell Carcinoma | July 1, 2025
Professor Bex discusses the phase II NEOAVAX trial that evaluated avelumab/axitinib as neoadjuvant therapy in localized RCC.
Vignesh T. Packiam, MDNon-Muscle Invasive Urothelial Carcinoma | June 30, 2025
Drs. Packiam and Yerram conclude with an AI-powered pathology tool designed to predict response to BCG in NMIBC.